TNF and inflammatory bowel disease: However, other studies reported that perioperative use of vedolizumab was not associated with short-term (<30 days) post-operative complications in patients with IBD [15–17, 20] and that the risk was not greater than that reported for anti-TNFα or non-biologic therapy [15, 16, 20].